)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Ginkgo Bioworks
Ginkgo Bioworks (DNA) investor relations material
Ginkgo Bioworks Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Autonomous Labs equipment and Cloud Lab services were positioned as two offerings on one autonomous-lab platform; Q3 included the first autonomous-lab sale to Novo Nordisk.
Q3 revenue was $27.7M, down 6% YoY, while continuing-operations net loss and Adjusted EBITDA loss narrowed; FY26 cash-burn guidance was reaffirmed.
Financial highlights
Q3 revenue was $27.7M versus $29.4M; 9M revenue was $67.3M versus $106.7M.
Q3 continuing-operations net loss was $41.0M versus $73.4M; 9M continuing-operations net loss was $174.4M versus $209.9M.
Q3 Adjusted EBITDA loss was $22.3M versus $52.7M; 9M loss was $100.8M versus $122.3M.
Q3 cash burn was $27M versus $28M; 9M cash burn was $120M versus $124M.
Outlook and guidance
FY26 total cash-burn guidance was reaffirmed at $125M–$150M, compared with FY25 cash burn of $171M.
Priorities include increasing autonomous-lab sales to biopharma, national labs and research universities, and expanding Cloud Lab services.
Systems revenue is expected at installation, with recurring services and SaaS-like revenue building across the deployed fleet; typical installation lead times are 6–12 months.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Ginkgo Bioworks
- Revenue fell 48% as autonomous-lab expansion advanced and cash-burn guidance held.DNA
Q2 2026 - Q1 2026 revenue fell 49% to $19M as restructuring improved cash burn and focus shifted to autonomous labs.DNAQ1 2026
- Shareholders will vote virtually on directors, auditor, and executive pay, focusing on equity-based compensation.DNAProxy filing
- Director elections, auditor ratification, and say-on-pay up for vote at June 2026 meeting.DNAProxy filing
- Cash burn cut by 55% as focus shifts to autonomous labs and AI-driven automation partnerships.DNAQ4 2025
- Q3 revenue up 61% to $89M, loss narrows, and 2024 guidance raised to $215–235M.DNAQ3 2024
- Streamlined operations and new tools offerings drive a shift to a horizontal biotech platform.DNAMorgan Stanley 22nd Annual Global Healthcare Conference
- Q2 2024 revenue dropped 30% as restructuring and $47.9M goodwill impairment hit results.DNAQ2 2024
- Direct sales, biopharma partnerships, and automation drive growth and market leadership.DNA43rd Annual J.P. Morgan Healthcare Conference 2025
Next Ginkgo Bioworks earnings date
Q4 202626 Feb, 2027
Ginkgo Bioworks
Next Ginkgo Bioworks earnings date
Q4 202626 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Ginkgo Bioworks Holdings, Inc, a biomolecular engineering company, develops biological manufacturing technologies to program cells for molecular manufacturing systems. Ginkgo Bioworks Holdings software engineering platform uses the widely used programming language Python and its library of bioinformatics functions and statistical methods. Ginkgo Bioworks' programs are designed to modify bacterial genes to make organic compounds such as vanillin, scents to produce civetone in bacteria, Beta-carotene and lycopene in yeast cells, gluconic acid in E. coli; and shikimic acid and artemisinic acid in yeast cells. The company sells its products to pharmaceutical companies including AstraZeneca Group and Eli Lilly & Co; chemical companies including Firmenich SA; flavor, aroma, and fragrance companies; craft breweries; and others.